Moomoo AI 已提取核心訊息
On February 27, 2024, Arcutis Biotherapeutics, Inc., a Delaware-incorporated biopharmaceutical company, announced the signing of a significant License Agreement with Sato Pharmaceutical Co., Ltd., a Japanese firm. Under the agreement, Arcutis grants Sato an exclusive license to develop, manufacture, and commercialize two of its dermatological products, ZORYVE cream and foam, in Japan. The deal includes an upfront payment of $25 million to Arcutis, with the potential for additional regulatory and sales milestone payments totaling up to $40 million. Furthermore, Arcutis is set to receive royalties on net sales in Japan, ranging from low double-digit to mid-teen double-digit percentages, during the Royalty Term. The License Agreement will remain in effect until the end of the Royalty Term for each product and includes provisions for termination under certain conditions, such as material breach or insolvency. A detailed copy of the License Agreement will be included in Arcutis's upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.
On February 27, 2024, Arcutis Biotherapeutics, Inc., a Delaware-incorporated biopharmaceutical company, announced the signing of a significant License Agreement with Sato Pharmaceutical Co., Ltd., a Japanese firm. Under the agreement, Arcutis grants Sato an exclusive license to develop, manufacture, and commercialize two of its dermatological products, ZORYVE cream and foam, in Japan. The deal includes an upfront payment of $25 million to Arcutis, with the potential for additional regulatory and sales milestone payments totaling up to $40 million. Furthermore, Arcutis is set to receive royalties on net sales in Japan, ranging from low double-digit to mid-teen double-digit percentages, during the Royalty Term. The License Agreement will remain in effect until the end of the Royalty Term for each product and includes provisions for termination under certain conditions, such as material breach or insolvency. A detailed copy of the License Agreement will be included in Arcutis's upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.
2024年2月27日，特拉華州註冊的生物製藥公司Arcutis Biotherapeutics, Inc. 宣佈與日本公司佐藤製藥有限公司簽署了一項重要的許可協議。根據該協議，Arcutis授予佐藤獨家許可，允許其在日本開發、製造和商業化其兩種皮膚科產品，即ZORYVE乳霜和泡沫。該交易包括向Arcutis預付2500萬美元，並有可能獲得總額高達4000萬美元的額外監管和銷售里程碑款項。此外，Arcutis將在特許權使用費期限內獲得日本淨銷售額的特許權使用費，從低的兩位數到中等的兩位數百分比不等。許可協議將一直有效，直到每種產品的特許權使用費期限結束，其中包括在某些條件下終止的條款，例如重大違規或破產。許可協議的詳細副本將包含在Arcutis即將發佈的截至2024年3月31日的季度10-Q表季度報告中。
2024年2月27日，特拉華州註冊的生物製藥公司Arcutis Biotherapeutics, Inc. 宣佈與日本公司佐藤製藥有限公司簽署了一項重要的許可協議。根據該協議，Arcutis授予佐藤獨家許可，允許其在日本開發、製造和商業化其兩種皮膚科產品，即ZORYVE乳霜和泡沫。該交易包括向Arcutis預付2500萬美元，並有可能獲得總額高達4000萬美元的額外監管和銷售里程碑款項。此外，Arcutis將在特許權使用費期限內獲得日本淨銷售額的特許權使用費，從低的兩位數到中等的兩位數百分比不等。許可協議將一直有效，直到每種產品的特許權使用費期限結束，其中包括在某些條件下終止的條款，例如重大違規或破產。許可協議的詳細副本將包含在Arcutis即將發佈的截至2024年3月31日的季度10-Q表季度報告中。
有用
沒用